937 related articles for article (PubMed ID: 20102879)
1. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial.
Jarai R; Huber K; Bogaerts K; Droogne W; Ezekowitz J; Granger CB; Sinnaeve PR; Ross AM; Zeymer U; Armstrong PW; Van de Werf FJ;
Am Heart J; 2010 Jan; 159(1):131-40. PubMed ID: 20102879
[TBL] [Abstract][Full Text] [Related]
2. Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis.
Sinnaeve PR; Ezekowitz JA; Bogaerts K; Droogne W; Jarai R; Huber K; Granger CB; Desmet WJ; Armstrong PW; Van de Werf FJ;
Eur Heart J; 2009 Sep; 30(18):2213-9. PubMed ID: 19586960
[TBL] [Abstract][Full Text] [Related]
3. Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome.
Buchner S; Debl K; Barlage S; Griese D; Fredersdorf S; Jeron A; Lubnow M; Müller T; Muders F; Holmer S; Riegger GA; Luchner A
Clin Chem Lab Med; 2010 Jun; 48(6):875-81. PubMed ID: 20441480
[TBL] [Abstract][Full Text] [Related]
4. Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?
Ezekowitz JA; Théroux P; Welsh R; Bata I; Webb J; Armstrong PW
Can J Physiol Pharmacol; 2007 Jan; 85(1):173-8. PubMed ID: 17487257
[TBL] [Abstract][Full Text] [Related]
5. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention.
Kwon TG; Bae JH; Jeong MH; Kim YJ; Hur SH; Seong IW; Cho MC; Seung KB; Jang YS; Park SJ;
Int J Cardiol; 2009 Apr; 133(2):173-8. PubMed ID: 18281115
[TBL] [Abstract][Full Text] [Related]
6. Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score.
Schellings DA; Adiyaman A; Giannitsis E; Hamm C; Suryapranata H; Ten Berg JM; Hoorntje JC; Van't Hof AW
J Am Heart Assoc; 2014 Nov; 3(6):e001089. PubMed ID: 25389283
[TBL] [Abstract][Full Text] [Related]
7. Reduced-dose fibrinolytic acceleration of ST-segment elevation myocardial infarction treatment coupled with urgent percutaneous coronary intervention compared to primary percutaneous coronary intervention alone results of the AMICO (Alliance for Myocardial Infarction Care Optimization) Registry.
Denktas AE; Athar H; Henry TD; Larson DM; Simons M; Chan RS; Niles NW; Thiele H; Schuler G; Ahn C; Sdringola S; Anderson HV; McKay RG; Smalling RW
JACC Cardiovasc Interv; 2008 Oct; 1(5):504-10. PubMed ID: 19463352
[TBL] [Abstract][Full Text] [Related]
8. Plasma B-type natriuretic peptide level can predict myocardial tissue perfusion in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Seo SM; Kim S; Chang K; Min J; Kim TH; Koh YS; Park HJ; Shin WS; Lee JM; Kim PJ; Chung WS; Seung KB
Coron Artery Dis; 2011; 22(6):405-10. PubMed ID: 21701385
[TBL] [Abstract][Full Text] [Related]
9. Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial.
Zalewski J; Bogaerts K; Desmet W; Sinnaeve P; Berger P; Grines C; Danays T; Armstrong P; Van de Werf F
J Am Coll Cardiol; 2011 May; 57(19):1867-73. PubMed ID: 21545942
[TBL] [Abstract][Full Text] [Related]
10. The impact of NT-proBNP on admission for early risk stratification of patients undergoing primary percutaneous coronary intervention.
Ayhan E; Isık T; Uyarel H; Ergelen M; Cicek G; Ozyurtlu F; Ghannadian B; Tanboga IH
Kardiol Pol; 2013; 71(2):165-75. PubMed ID: 23575711
[TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction: the Athens PCI trial.
Kanakakis J; Nanas JN; Tsagalou EP; Maroulidis GD; Drakos SG; Ntalianis AS; Tzoumele P; Skoumbourdis E; Charbis P; Rokas S; Anastasiou-Nana M
Catheter Cardiovasc Interv; 2009 Sep; 74(3):398-405. PubMed ID: 19360864
[TBL] [Abstract][Full Text] [Related]
12. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals.
Herrmann HC; Lu J; Brodie BR; Armstrong PW; Montalescot G; Betriu A; Neuman FJ; Effron MB; Barnathan ES; Topol EJ; Ellis SG;
JACC Cardiovasc Interv; 2009 Oct; 2(10):917-24. PubMed ID: 19850249
[TBL] [Abstract][Full Text] [Related]
13. Relation of corrected thrombolysis in myocardial infarction frame count and ST-segment resolution to myocardial tissue perfusion after acute myocardial infarction.
Li CM; Zhang XH; Ma XJ; Zhu XL
Catheter Cardiovasc Interv; 2008 Feb; 71(3):312-7. PubMed ID: 18288744
[TBL] [Abstract][Full Text] [Related]
14. Different treatment interventions affect plasma NT-ProBNP levels and early exercise tolerance in patients with acute ST-segment elevation myocardial infarction.
Wu XL; Zhu R; Jiang H; Li B
Postgrad Med; 2012 Mar; 124(2):58-63. PubMed ID: 22437216
[TBL] [Abstract][Full Text] [Related]
15. Multiple biomarkers at admission are associated with angiographic, electrocardiographic, and imaging cardiovascular mechanistic markers of outcomes in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.
Damman P; Kuijt WJ; Woudstra P; Haeck JD; Koch KT; Gu YL; van Straalen JP; Fischer J; Tijssen JG; Krucoff MW; de Winter RJ
Am Heart J; 2012 May; 163(5):783-9. PubMed ID: 22607855
[TBL] [Abstract][Full Text] [Related]
16. Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention.
Fabris E; Ottervanger JP; Hermanides RS; Ten Berg JM; Sinagra G; Koopmans PC; Giannitsis E; Hamm C; van 't Hof AWJ
Catheter Cardiovasc Interv; 2019 Apr; 93(5):E293-E297. PubMed ID: 30585388
[TBL] [Abstract][Full Text] [Related]
17. N-terminal pro-brain natriuretic peptide is a biomarker of congestive heart failure and predictive of 30-day untoward clinical outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Wu CJ; Chang HW; Hung WC; Yang CH; Chen YH; Su CY; Yip HK
Circ J; 2006 Feb; 70(2):163-8. PubMed ID: 16434809
[TBL] [Abstract][Full Text] [Related]
18. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention.
Akpek M; Kaya MG; Lam YY; Sahin O; Elcik D; Celik T; Ergin A; Gibson CM
Am J Cardiol; 2012 Sep; 110(5):621-7. PubMed ID: 22608360
[TBL] [Abstract][Full Text] [Related]
19. Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials).
Brener SJ; Mehran R; Brodie BR; Guagliumi G; Witzenbichler B; Cristea E; Xu K; Lansky AJ; Stone GW
Am J Cardiol; 2011 Oct; 108(7):918-23. PubMed ID: 21764028
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy.
Tang WH; Steinhubl SR; Van Lente F; Brennan D; McErlean E; Maroo A; Francis GS; Topol EJ
Am Heart J; 2007 Jan; 153(1):36-41. PubMed ID: 17174634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
